DAXSINIG

Serial Number 98804013
730

Registration Progress

Application Filed
Oct 16, 2024
Under Examination
Feb 18, 2025
Approved for Publication
Dec 24, 2024
Published for Opposition
Dec 24, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 1 Granted
Due: Feb 18, 2026 224 days

Basic Information

Serial Number
98804013
Deadline
February 18, 2026
Description
Statement of Use or 2nd Extension Due
Filing Date
October 16, 2024
Published for Opposition
December 24, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Jul 3, 2025
Application
Pending
Classes
005

Rights Holder

Pfizer Inc.

03
Address
66 Hudson Boulevard East
New York, NY 10001-2192

Ownership History

Pfizer Inc.

Original Applicant
03
New York, NY

Pfizer Inc.

Owner at Publication
03
New York, NY

Legal Representation

Attorney
Janina Gorbach

USPTO Deadlines

Next Deadline
224 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
February 18, 2026
Extension Available
Until February 18, 2026

Application History

12 events
Date Code Type Description
Jul 3, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 3, 2025 EX1G S SOU EXTENSION 1 GRANTED
Jul 2, 2025 EXT1 S SOU EXTENSION 1 FILED
Jul 2, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 18, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 24, 2024 PUBO A PUBLISHED FOR OPPOSITION
Dec 24, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 18, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 25, 2024 DOCK D ASSIGNED TO EXAMINER
Oct 16, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 16, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for treatment of dermatomyositis and lupus

Classification

International Classes
005